european medicines agency glp-1 vision loss recommendation november 2025 Ozempic Lawsuit: July 2026 Blindness and Gastroparesis Claims EMA tells countries to prioritise

Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)

Many patients wonder whether berberine and Wegovy can be used together safely

In fact, your focus needs to be on weight training so you can keep muscle and maintain a healthy metabolism.

Work from my lab and from David Furman at the Buck has focused on developing novel immune clocks: tools that assess how old your immune system is, independent of your chronological age